Methamphetamine (METH) abuse is a worldwide threat, without any FDA approved medications. Anti-METH IgGs and single chain fragments (scFvs) have shown efficacy in preclinical studies. Here we report affinity enhancement of an anti-METH scFv for METH and its active metabolite amphetamine (AMP), through the introduction of point mutations, rationally designed to optimize the shape and hydrophobicity of the antibody binding pocket. The binding affinity was measured using saturation binding technique. The mutant scFv-S93T showed 3.1 fold enhancement in affinity for METH and 26 fold for AMP. The scFv-I37M and scFv-Y34M mutants showed enhancement of 94, and 8 fold for AMP, respectively. Structural analysis of scFv-S93T:METH revealed that the substitution of Ser residue by Thr caused the expulsion of a water molecule from the cavity, creating a more hydrophobic environment for the binding that dramatically increases the affinities for METH and AMP. However, there are no FDA approved medications to treat METH addiction and thus effective treatments are greatly needed. Current METH addiction treatments mainly comprise behavior modifications or palliative interventions which only relieve some organ-based symptoms. These approaches neither remove nor block METH from its sites of action, rendering them ineffective in reducing METH-related medical complications and formation of its toxic metabolites. Moreover, the effectiveness of stand-alone cognitive-behavioral therapy for METH addiction is challenging, since METH addiction has the highest relapse rates of any illicit drug addiction 2, 3 . In pursuit of effective treatments for METH abuse, that could be used in conjunction with behavioral therapies, anti-METH monoclonal antibodies (mAbs) have been developed 4, 5 . The first generation mAbs have been well characterized in vivo and in vitro 6-8 and have shown significant preclinical efficacy. In METH abuse rodent models, anti-METH mAbs significantly reduce METH brain concentrations and relapse to METH self-administration and shorten the duration of METH-induced locomotor activity [9] [10] [11] . A chimeric anti-METH mAb, ChmAb7F9, developed from these endeavors is now in Phase 1 clinical trials.
However, there are no FDA approved medications to treat METH addiction and thus effective treatments are greatly needed. Current METH addiction treatments mainly comprise behavior modifications or palliative interventions which only relieve some organ-based symptoms. These approaches neither remove nor block METH from its sites of action, rendering them ineffective in reducing METH-related medical complications and formation of its toxic metabolites. Moreover, the effectiveness of stand-alone cognitive-behavioral therapy for METH addiction is challenging, since METH addiction has the highest relapse rates of any illicit drug addiction 2, 3 . In pursuit of effective treatments for METH abuse, that could be used in conjunction with behavioral therapies, anti-METH monoclonal antibodies (mAbs) have been developed 4, 5 . The first generation mAbs have been well characterized in vivo and in vitro [6] [7] [8] and have shown significant preclinical efficacy. In METH abuse rodent models, anti-METH mAbs significantly reduce METH brain concentrations and relapse to METH self-administration and shorten the duration of METH-induced locomotor activity [9] [10] [11] . A chimeric anti-METH mAb, ChmAb7F9, developed from these endeavors is now in Phase 1 clinical trials.
These anti-METH mAbs act as pharmacokinetic antagonists by retaining METH in the vasculature and thus sequestering it from its sites of action in the brain and heart. The variable domains of the heavy and light chains form METH binding cavities in these IgG molecules. Since only these variable regions are involved in direct interactions with the ligand, we have constructed an anti-METH single-chain variable-fragment (ScFv) from one of our most potent mAb, mAb6H4 (IgG, k light chain, K D 5 4 nM, measured using radioimmunoassay). The constructed scFv6H4 showed no change in affinity for METH with mAb6H4 12 . This scFv format has some clear advantages over the mAb format. In particular the scFv can be produced more economically and since it is only one-sixth of the size of the original antibody, the protein dosage required to deliver the same number of binding fragments is one-third that of the mAb (IgG).
Despite of their promise the current anti-METH scFv, as well as the available mAbs are challenged by the fact that they have very low affinity for amphetamine (AMP) (Figure 1 a) . AMP is pharmacologically active metabolite (Figure 1 a) , produced by demethylation in the body. Although AMP is less potent stimulant than METH, an immunotherapy capable of removing both of these drugs from their site of action would be highly desirable. Therefore we sought to generate mutants of scFv6H4 with enhanced binding affinity for both METH and AMP improving its therapeutic potential. Unfortunately, hapten design studies suggest that we might have reached the limit of generating very high affinity antibodies by traditional immunization methods 12 . Indeed, screening over 30,000 cell lines from mice immunized with METH-conjugate vaccines, failed to produce a mAb with high affinity for both METH and AMP 13 . Designing antibodies that bind with high affinity and specificity to small molecule drugs of abuse is extremely challenging. METH has a calculated surface area of 206 Å 2 with only one charged atom available for hydrogen bonding at physiological pH (,7.4). Thus, in order to engineer scFvs with high METH and AMP binding affinities, we turned to X-ray crystallography data of scFv6H4 in complex with METH.
The crystal structure of the scFv6H4:METH complex shows METH sitting in a deep pocket with the cationic amino tail pointing towards the bottom of the pocket (Figure 1b) 14 . Aromatic residues from the complementarity determining region (CDR) loops of the light and heavy chains form a hydrophobic barrel around the phenyl ring of METH covering 75% of its total surface area 14 (Figure 1 b) . The secondary amine of METH forms a hydrogen bond with the imidazole ring of His89 of the light chain and another hydrogen bond with the carboxylate of Glu101 from the heavy chain. In addition to METH, the pocket accommodates two water molecules which form hydrogen bonds with the two Ser residues SerH35 and SerH93.
We hypothesized that the affinity of an anti-METH scFv6H4 to METH and AMP could be enhanced using structure-driven mutations aimed to optimize the shape and the hydrophobicity of the binding pocket. Due to the small size of METH (149.23 Da) and the very limited number of critical binding interactions with the antibody, the precise crystallographic delineation of these interactions were vital in our efforts to enhance binding affinity. From these efforts we developed scFv-S93T, an antibody that shows highly enhanced affinity for both METH and AMP. In this report, we also present the high-resolution crystal structure of scFv-S93T in complex with METH. Clinically, this antibody, could be an ideal candidate for treating METH overdose, or could be serve as the basis of further customization.
In addition to scFv-S93T, we designed and constructed four additional scFv6H4 mutants: scFv-I37M, scFv-Y34W, scFv-Y34M and scFv-H89E. We found that three of the mutants (scFv-S93T, scFv-I37M, and scFv-Y34M) exhibited dramatically increased affinity to either METH or AMP, or both. Two of the mutants (scFv-Y34W and scFv-H89E) resulted in substantially lower affinity or lacked binding activity altogether, underscoring the fragile balance of complex interactions between METH and the binding pocket.
Results
We designed the following mutations (shown in Figure 2 a and b) with the corresponding rationale for each mutation. S93T Mutation: As METH and AMP have only one charged atom each (Figure 1 a) and as both have a predominant hydrophobic nature, we sought to increase the hydrophobic character of the binding pocket by forcing a water molecule out, while preserving the side chain charges for the most part. The Ser H93 residue located on the sidewall of the cavity interacts with a water molecule and was replaced with a slightly larger residue threonine. I37M Mutation: We substituted an isoleucine residue situated at the bottom of the pocket with a longer residue methionine (IleH37Met). The binding pocket of I37M has potential for tighter packing environment for METH and AMP. H89E Mutation: The cationic nitrogen of METH forms two hydrogen bonds of different strength with HisL89 and GluH101. The hydrogen bond with GluH101 is stronger compared to HisL89. We substituted histidine with glutamic acid to make both interactions equally strong. Y34M and Y34W Mutations: In order to generate a mutant of scFv that binds to both METH and AMP with high affinity, we substituted the aromatic residue tyrosine with a methionine (Y34M) and tryptophan (Y34W) residue. The bulkier side chain of tryptophan could compliment the loss of the methyl group in AMP (Figure 1 a) , provided it adopted a favorable conformation. The methionine side chain is more flexible and therefore, we anticipated that it could adopt a suitable conformation to optimize packing for AMP or METH.
In vitro affinity for METH. All the newly produced scFv6H4 mutants scFv-S93T, scFv-I37M, scFv-Y34M, scFv-Y34W and svFv-H89E were tested for METH affinity. The dissociation constants (K D ) were measured using saturation binding equilibrium dialysis experiments between scFvs and METH. The K D (6SEM) for wild type scFv6H4 is 0.79 (60. 19 scFv-Y34W and svFv-H89E affinity for AMP were below our threshold of 50 mM affinity. The mutants scFv-S93T, scFv-I37M and scFv-Y34M showed statistically significant improvement in affinity for AMP with respect to wild type scFv6H4 (p , 0.01) by 26, 94 and 8 fold, respectively (Figure 3 d) .
Deleterious mutations. Ligand binding is a delicate balance involving a multitude of complex interactions and some changes in the binding pocket could have negative effects. Two of the mutants (H89E and the Y34W) did not show any measurable affinity for METH or AMP (data not shown). HisL89 forms a hydrogen bond with the cationic nitrogen and the replacement of His with a negatively charged residue appeared to have caused an unfavorable electrostatic environment for binding. The replacement of Tyr with a larger residue Trp (Y34W) was intended to create a tighter environment for AMP, but the mutation appears to have caused disruption of the pocket and nearly complete loss of binding. However, replacement of Tyr by a more flexible Met (Y34M) enhanced the AMP binding significantly and reduced binding slightly for METH.
Crystal structure of scFv-S93T:METH. In order to examine the structural basis for the enhancement of affinity, we analyzed the crystal structure of the scFv-S93T mutant in complex with METH at 2.0 Å resolution. The structure was refined to R factor and R free of 19.4 and 25.4% respectively ( Table 1 ). The overall structure of the S93T is similar to the native structure Role of water molecule interactions with hydrocarbon atoms in METH binding. As shown in Figure 5 , the replacement of SerH93 by a ThrH93 resulted in the expulsion of a water molecule from the binding pocket, improving the affinity for both METH and AMP. In the case of anti-METH scFv6H4, the binding pocket has considerable hydrophobic characteristics, yet has two water molecules buried deep inside. These waters do not form any hydrogen bonds with the amide nitrogen of METH, but participate in hydrogen bonding interactions with backbone carbonyl atoms and side chain hydroxyl atoms of Ser residues (Figure 5 a) . The water molecule Ow5 participates altogether in four and Ow6 in three hydrogen bond interactions. Ow6 however has two contacts with hydrophobic hydrocarbon atoms of METH molecule with contact distances of 4.0 and 4.2 Å (Figure 5 a) , but the Ser O c atom is farther away (6.5 Å ) from these hydrocarbon atoms. Compared to the native structure, the scFv-S93T mutant is devoid of the water molecule Ow6, but has an extra methyl group by virtue of the mutation. Therefore the mutation increases the hydrophobic character of the pocket and alters some interactions in the pocket. The side chain of Thr residue is oriented to form a hydrogen bond between its c-oxygen atom and Ow5. At this position, the c-oxygen atom has moved slightly towards the METH compared to the Ser residue in the native structure, but still keeping distances of 6.1 and 6.0 Å from the hydrocarbon atoms of METH (Figure 5 b) . Therefore, the mutation increases the separation between the hydrophilic oxygen and the hydrocarbon atoms.
Discussion
The purpose of the study was to design higher affinity antibodies against METH and AMP. The affinity of an antibody for its ligand (expressed in terms of K D ) indicates the degree of binding site occupancy at a given concentration. In other words, a higher affinity antibody will bind and neutralize more METH or AMP at a given drug concentration than a lower affinity antibody. Thus, to ensure the highest efficacy based on a wide range of potential serum concentrations of METH, antibody affinity should be maximized. Indeed it has been shown in animal models that the higher affinity anti-METH mAbs are significantly more effective than low affinity mAbs 4, 6 . The present study shows that the structure-based engineering has promise as a technique for producing higher affinity antibodies as therapeutic agents for small molecules such as drugs of abuse. In vitro techniques that are commonly employed to improve affinity of antibodies to their antigens include phage display, yeast display and ribosomal display [15] [16] [17] [18] . These methods introduce mutations randomly throughout the entire sequence and use a variety of selection processes to screen for high affinity antibodies, and have been successful for a variety of antibody targets. METH, however, poses a special challenge due to its smaller size and the limited number of residues that directly interact with it. Therefore, we employed a structure-based method to improve the affinity by remodeling the METH binding pocket. Through this approach, we were able to increase the affinity to METH and its active metabolite AMP by designing and testing a small number of mutants based on crystallographic information. The usefulness of structure-based drug design is well documented 19, 20 . For example, using structure-based computational techniques, Clark et al improved the affinity of an antibody fragment against the I-domain of integrin VLA1 20 . In that case however, the interacting surface was more extensive than in the METH antibody reported here. There were a large number of residues involved in the molecular interactions, resulting in many more parameters available for manipulation. The METH binding, on the contrary, presents an extreme situation with a limited number of parameters. This study also underscores the role of water molecules in ligand binding as demonstrated by the high affinity mutant scFv-S93T. Since hydrophobic interactions were first described by Walter Kauzmann more than five decades ago 21 , their crucial role in protein folding and ligand binding has become evident. Structured water molecules in the binding pocket play an important role in ligand binding. Ordered water molecules can modify the environment of the binding pocket to optimize binding through favorable interactions. In certain cases, however, the presence of a water molecule may generate less favorable contacts and removal of those water molecules could promote binding. In the present study, the introduction of a methyl group through the substitution of Ser R Thr, a water molecule could be expelled increasing the affinities for both METH and AMP.
There are other examples of water molecules altering the affinity of proteins to ligands and other proteins. An illustration of water molecules amending the specificity and affinity favorably to accommodate variations in the ligands is provided by the crystal structures of Larabinose-binding protein in complex with L-arabinose, D-fucose and D-galactose 22 . These structures show that the water molecules can adjust their position or even move out of the cavity to accommodate size, shape or hydrophobicity variations of the ligand. An example illustrating the crucial role of water molecules in proteinprotein interactions is the crystal structure of the Ile R Val mutant of von Willebrand factor A1 domain. The mutation led to incorporation of a water molecule into the protein structure increasing its affinity for the receptor glycoprotein 23 . The scFv-S93T crystal structure presents a different scenario where a water molecule moves out in response to the increased hydrophobicity and the shrinkage of the pocket size favorably for METH and AMP binding.
The overall purpose of this study was to utilize the anti-METH scFv6H4 crystal structure to design rational point mutations to identify high affinity mutants. Three of the five mutants that we generated showed significant improvement in binding to either METH or AMP, or both. We determined the crystal structure of the highest affinity mutant, scFv-S93T, revealing the important loss of a water from the binding pocket. We utilized the scFv platform for affinity improvement due to its ease of production, structural studies and sequence manipulation 24 . Clinically, with its short half-life, scFv is an ideal candidate for treating METH overdose and could be adapted for longer-term clinical use through molecular customization such as conjugation to polyethylene glycol or potentially even nanoparticles 25 . These mutants could be further tailored to chimeric or humanized mAbs for preclinical and clinical testing.
Methods
Cloning of anti-METH scFv6H4 mutants. Point mutations were created in scFv6H4 (wild type) sequence to make scFv-S93T, scFv-Y34M scFv-Y34W, scFv-I37M and scFv-H89E following the procedures described in Molecular Cloning: A Laboratory Manual 26 . Mutants were engineered with EcoRI restriction site on N-terminus and on the carboxy terminus with His-tag and XbaI restriction site. ScFv6H4 mutants were synthesized using Genscript services and were received cloned in pUC57 vector. For maintenance, all the mutants were transformed into E. coli, DH5a (Invitrogen) cells. The transformed colonies were selected through ampicillin resistance. The mutants (scFv-S93T, scFv-Y34M, scFv-Y34W, scFv-I37M and scFv-H89E) cDNA were extracted from vector pUC57 using EcoRI and XbaI (NEB) restriction sites. DNA was then gel purified and ligated to the vector pPicza-A (Invitrogen) using the same restriction sites. The plasmids were transformed into E. coli, DH5a (Invitrogen) cells for amplification on LB Agar plates and selected through ampicillin resistance. Plasmids were isolated and tested for mutation and in-frame cloning by PCR amplification, restriction digestion and DNA sequencing (University of Arkansas for Medical Sciences DNA sequencing core facility). Plasmids were linearized using SacI (NEB) and transformed into Pichia pastoris, X33 cells using electroporation. Transformed colonies containing cDNA of scFv6H4 mutants were selected using Zeocin (Invitrogen) resistance on YPD (Yeast Extract Peptone Dextrose) agar plates.
Expression of anti-METH scFv6H4 mutants. Selected transformed colonies with strong Zeocin resistance were tested for the expression of scFv-S93T, scFv-Y34M scFv-Y34W, scFv-I37M and scFv-H89E. For expression, selected colonies were inoculated in BMGY (Buffered Glycerol-complex Medium) for amplification. For scFv6H4 mutants expression, cells were harvested and re-suspended into BMMY (Buffered Glycerol-complex Medium). Protein expression was induced by feeding to a final v/v concentration of 0.5% of methanol at 24, 48, 72 and 96 hr. ScFv6H4 mutant proteins containing His-tag in its carboxy terminus were secreted into the media. The protein sample in media was collected after centrifugation at 15000 g for 15 min. The supernatant was tested for expression using SDS-PAGE.
Purification of anti-METH scFv6H4 mutants. The expressed scFv6H4 mutants were purified using nickel sepharose immobilized metal affinity chromatography, HiPrep FF 16/10 column (GE healthcare). ScFv6H4 mutants were purified in onestep elution using elution buffer (20 mM sodium phosphate buffer, 500 mM NaCl and 500 mM imidazole, pH 7.4). Collected fractions were pooled, buffer exchanged and concentrated to 1.4 mg/ml in scFv administration buffer (15 mM sodium phosphate buffer and 150 mM NaCl, pH 7.4) for binding studies.
Saturation equilibrium dialysis to determine K D for METH affinity. Binding of scFv6H4, scFv-S93T, scFv-Y34M and scFv-I34M with METH was tested using Rapid Equilibrium Dialysis devices (RED, Thermo Scientific) with inserts of 6-8 kDa MWCO membranes. Saturation binding assay was performed as described in Nanaware-Kharade et al 25 . The scFv concentration used in all saturation binding experiments was optimized to maximize the signal to noise ratio as well as minimize errors resulting from possible ligand depletion. The saturation binding experiment involves two parts: determination of total and non-specific binding. Total binding was determined by saturating scFv with the increasing concentration of 3 H-METH in range 0.01 to 40 nM. To determine the non-specific binding, we added 10 mM of unlabeled METH as a competitor of 3 H-METH. Data points were tested in triplicates, and at least three independent experiments were performed for each scFv.
Inhibition equilibrium dialysis to determine IC 50 values for AMP affinity. Binding affinity of scFv6H4 and mutants to AMP was determined using the RED devices described above. Titration experiments were used to determine the concentration of scFv6H4, scFv-S93T, scFv-Y34M, scFv-I34M, scFv-H89E and scFv-Y34W that will bind to 20% of a 3 H-AMP solution of 50,000 dpm and used for the competition binding experiment. In this experiment a constant concentration of 3 H-AMP 50,000 dpm was allowed to compete with various concentrations of AMP (0.01-1000 mM). Protein was placed on the sample side and on the buffer side constant 3 H-AMP and increasing concentrations of AMP were placed. Each concentration of AMP was tested in triplicate. Plates were sealed and gently shaken for 18 hr at room temperature to achieve equilibrium between sample side (red) and buffer side (white). To determine binding, 50 ml aliquots were taken from the sample and the buffer sides separately and quantified using liquid scintillation spectrophotometry.
Data analysis for comparison of affinities. For evaluating METH binding we measured the K D , while for AMP we measured the IC 50 . At least three independent experiments were performed with each scFv to test the METH and AMP affinities. K D for METH saturation binding was determined using nonlinear curve fitting accounting for specific and nonspecific binding. IC 50 for AMP inhibition binding was determined using the percent bound vs. AMP concentration curve 27 . Unpaired, onetailed Student's t-test was performed to obtain the statistical significance of the differences in binding affinities. K D s of scFv mutants observed from three independent experiments were compared with K D s of scFv6H4 and statistical significance was calculated for the difference in affinities. The same analysis was repeated for the comparison of AMP affinities using IC 50 values from three independent experiments. Fold changes were calculated using the mean of the respective affinity values (K D or IC 50 ) observed for scFv mutants and compared with mean of K D or IC 50 observed for the wild type scFv6H4 for the respective analysis. Saturation and inhibition binding figures were generated using Graphpad Prism 5.0d software.
Crystallization and data collection of scFv-S93T in complex with METH. For crystallization, the protein sample was concentrated to 12.3 mg/ml in a buffer containing 5 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 150 mM sodium chloride, and 5 mM octyl b-D-glucopyranoside detergent at pH 8.3 using the 20 ml Pierce concentrators with 9 kDa molecular weight cut off (MWCO) membrane. METH was added to the protein solution to a final concentration of 5 mM. All the crystals scFV-S93T:METH were grown using the vapor diffusion, hanging drop method at 287 K. Initial screening of crystallization was designed based on the crystal condition of scFv6H4 14 . For scFv-S93Tcrystallization, 500 ml of reservoir solution contained 0.917 M sodium citrate pH 8.2, 0.324 M Imidazolemalate at pH 8.3. Hanging drops were made using 1 ml protein and 1 ml reservoir solution. The crystals grew in 3-4 weeks at 287 K. Using the reservoir solution as a cryo-protectant, the crystals were flash cooled in liquid nitrogen. The diffraction data were collected at Stanford Synchrotron Radiation Laboratory (SSRL), Palo Alto, CA.
Structure determination and refinement of scFv-S93T:METH. Diffraction data were indexed and scaled using the software package HKL2000 28 . The structure solution was carried out using the scFv6H4:METH structure as the starting model 14 .
The model building was carried out using the program COOT 29 and the refinement of the structure was carried out using the program Refmac5 30 in the CCP4 suite of programs 31 with 2.0 Å diffraction data. refinement statistics. Ray-traced graphics for structure figures were produced using The PyMOL Molecular Graphics System, Version 1.5.0.4 (Schrödinger, LLC).
